Results 231 to 240 of about 176,720 (311)

Intragastric Balloon Treatment Enhances Weight Maintenance Adjunct to Low‐Energy Diet and Group‐Based Cognitive Behavioural Therapy: A Randomized Controlled Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Low‐energy diet (LED) plus cognitive‐behavioural therapy (CBT) produces substantial short‐term weight loss in obesity, but long‐term maintenance remains difficult. We evaluated whether adding intragastric balloon (IGB) treatment to group‐based CBT improves weight maintenance after initial weight loss using LED.
Marije Galavazi   +6 more
wiley   +1 more source

Enriched Metabolic Phenotyping Refines Phenotypic Resolution of Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Data‐driven clustering studies of type 2 diabetes (T2D) based on limited routine clinical variables have reproducibly described major metabolic subgroups, including severe insulin‐deficient diabetes (SIDD), severe insulin‐resistant diabetes (SIRD), mild obesity‐related diabetes and mild age‐related diabetes.
Min Wang   +6 more
wiley   +1 more source

Association of Physical Activity With All‐Cause and CVD Mortality Across Metabolic and Obesity Phenotypes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To examine the independent and joint associations of metabolic status, obesity, and physical activity with all‐cause and cardiovascular disease (CVD) mortality across metabolic–obesity phenotypes. Materials and Methods We analysed 442 666 adults from the Korean National Health Insurance Service health screening cohort (2009–2012 ...
Yunmin Han   +3 more
wiley   +1 more source

Higher Serum Testosterone Protects Against the Development of Type 2 Diabetes in Middle‐Aged but Not Older Men

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Low serum testosterone concentration has been reported to be causally linked to the risk of Type 2 diabetes (T2D). The benefit of T2D protection has been demonstrated to continue up to serum testosterone concentrations of 461 ng/dL (16 nmol/L).
Mahesh M. Umapathysivam   +5 more
wiley   +1 more source

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy